Mirum Pharmaceuticals Inc (MIRM)
24.07
-0.68
(-2.75%)
USD |
NASDAQ |
May 17, 16:00
24.07
0.00 (0.00%)
After-Hours: 20:00
Mirum Pharmaceuticals SG&A Expense (Quarterly): 45.64M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 45.64M |
| December 31, 2023 | 46.18M |
| September 30, 2023 | 36.53M |
| June 30, 2023 | 32.95M |
| March 31, 2023 | 30.22M |
| December 31, 2022 | 26.47M |
| September 30, 2022 | 22.51M |
| June 30, 2022 | 20.97M |
| March 31, 2022 | 19.12M |
| December 31, 2021 | 19.04M |
| September 30, 2021 | 17.35M |
| Date | Value |
|---|---|
| June 30, 2021 | 13.35M |
| March 31, 2021 | 9.479M |
| December 31, 2020 | 7.225M |
| September 30, 2020 | 5.732M |
| June 30, 2020 | 5.042M |
| March 31, 2020 | 4.692M |
| December 31, 2019 | 4.278M |
| September 30, 2019 | 3.708M |
| June 30, 2019 | 2.445M |
| March 31, 2019 | 1.321M |
| September 30, 2018 | 0.062M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
2.445M
Minimum
Jun 2019
46.18M
Maximum
Dec 2023
18.65M
Average
18.19M
Median
SG&A Expense (Quarterly) Benchmarks
| Vanda Pharmaceuticals Inc | 30.08M |
| Sarepta Therapeutics Inc | 127.00M |
| Puma Biotechnology Inc | 21.64M |
| Reneo Pharmaceuticals Inc | 4.622M |
| Tharimmune Inc | 1.322M |